EXACT Sciences Corporation (NASDAQ: EXAS), a research and development company focused on developing non-invasive screening technologies for early detection of colorectal cancer, recently announced published results of a comprehensive colorectal cancer detection study in which stool and blood plasma were individually assessed to determine which type of testing was more accurate in detecting the dis

There has been a lot of strong recommendations around biotech lately on Contrarian Profits. Phase 1 Investor editor Rob Fannon recently wrote that biotech was one of the few market sectors to show positive returns as many other stocks were getting hammered. He sees great values in the sector.

If the deal does go through it may be bad news for Roche and Genentech shareholders, according to Phase 1 Investor editor Rob Fannon in The Growth Stock Wire. But it would be good news for the biotech industry as a whole…

Roche Holding has offered to buy the rest of Genentech, about a 44% stake it doesn't already own, for $89 a share, or about $43.7 billion.

The deal would mark one of the Swiss drug maker's biggest acquisitions and would mean about $750 million to $850 million in pre-tax savings.

Genentech will be releasing earnings after market close today. We have structured an options trade that will make money if the stock moves 2 points or more either way, with almost no downside. At most, you'll lost under a hundred dollars before commissions whereas if the stock moves 2 points or more, you make great money.

This is Jake Berzon of Odesskiy Listok's take on Fortune Magazines Best Best Stocks for 2008.

Annaly (NLY) – This company used to be on my watch list. It is a rather volatile stock that is in the current at-risk business (Fannie Mae and Freddie Mac are private companies), whose stock appreciated while all of the financials depreciated – so it is bigger gamble than I am willing to take.